AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33119435 — intervention group
Group type: EXPERIMENTAL
Intervention: High-negativity, self-referent statements
Number of subjects: 103
Study 33119435 — intervention group
Group type: COMPARATOR
Intervention: High-negativity, statements referring to another person
Number of subjects: 103
Study 33119435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-negativity, self-referent statements
Number of subjects: 103
Study 33119435 — intervention group
Group type: COMPARATOR
Intervention: Low-negativity, statements referring to another person
Number of subjects: 103
Study 33382529 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 × 10^6 CAR+ T-cells (low dose)
Number of subjects: 68
Study 33382529 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 × 10^6 CAR+ T-cells (high dose)
Number of subjects: 68
Study 33382529 — intervention group
Group type: COMPARATOR
Intervention: Lymphodepleting chemotherapy (fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 daily × 3)
Number of subjects: 68
Study 34026713 — intervention group
Group type: EXPERIMENTAL
Intervention: Msingi Bora intervention (group-based responsive stimulation and nutrition education)
Number of subjects: 60
Study 32174359 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye tracking measures
Number of subjects: 0
Study 32174359 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated forecasting decision aid
Number of subjects: 0
Study 37233875 — intervention group
Group type: EXPERIMENTAL
Intervention: Kukoamine B 0.06 mg/kg
Number of subjects: 24
Study 37233875 — intervention group
Group type: EXPERIMENTAL
Intervention: Kukoamine B 0.12 mg/kg
Number of subjects: 24
Study 37233875 — intervention group
Group type: EXPERIMENTAL
Intervention: Kukoamine B 0.24 mg/kg
Number of subjects: 24
Study 37233875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32588042 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 246
Study 32588042 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 246
Study 32588042 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 246
Study 32588042 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA (as-tested analysis)
Number of subjects: 246
Study 32301122 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 247
Study 32301122 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 247
Study 34675045 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol
Number of subjects: 984
Study 34675045 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 984
Study 34675045 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 984
Study 34675045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 984
Study 32212768 — intervention group
Group type: EXPERIMENTAL
Intervention: Purpose-guided trial design (PGTD)
Number of subjects: 0
Study 32212768 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic model for comparator selection
Number of subjects: 0
Study 32212768 — intervention group
Group type: EXPERIMENTAL
Intervention: PGTD framework
Number of subjects: 0
Study 36111243 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal bandage
Number of subjects: 239
Study 36111243 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 239
Study 32893836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked green banana in addition to standard care
Number of subjects: 0
Study 32893836 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 35927094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 0
Study 35927094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33808403 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron hydroxide adipate tartrate (IHAT) supplementation
Number of subjects: 17
Study 32063465 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarex
Number of subjects: 2
Study 32063465 — intervention group
Group type: COMPARATOR
Intervention: Angiojet
Number of subjects: 2
Study 32707561 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg body weight‐1)
Number of subjects: 26
Study 32707561 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (6 mg·kg‐1 dextrose)
Number of subjects: 26
Study 34617375 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg) added to insulin therapy
Number of subjects: 108
Study 34617375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 33713208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton (Bt RCH‐2) exposed to 200 mg/kg soil Cd
Number of subjects: 0
Study 33713208 — intervention group
Group type: COMPARATOR
Intervention: Cotton (Bt RCH‐2) exposed to 0 mg/kg soil Cd (control)
Number of subjects: 0
Study 33713208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton (Bt RCH‐2) exposed to various higher levels of Cd (200, 400, 600, 800, and 1000 mg/kg soil)
Number of subjects: 0
Study 33713208 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-microbe interaction with Aspergillus awamori
Number of subjects: 0
Study 32886536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory twice‐weekly clinical evaluation
Number of subjects: 311
Study 32886536 — intervention group
Group type: COMPARATOR
Intervention: Standard once‐weekly clinical evaluation
Number of subjects: 311
Study 33063477 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg once daily for 10 days
Number of subjects: 20
Study 33063477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34214937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib
Number of subjects: 364
Study 34214937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 34214937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib (in patients with brain metastases)
Number of subjects: 364
Study 34214937 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with brain metastases)
Number of subjects: 364
Study 35477877 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consultations
Number of subjects: 100
Study 35477877 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 34331766 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical therapy interventions
Number of subjects: 0
Study 34331766 — intervention group
Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 0
Study 35088177 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific femoral alignment guide (PSG)
Number of subjects: 80
Study 35088177 — intervention group
Group type: COMPARATOR
Intervention: Conventional pre-operative planning
Number of subjects: 80
Study 33481341 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly CERA administration
Number of subjects: 120
Study 33481341 — intervention group
Group type: COMPARATOR
Intervention: Biweekly CERA administration
Number of subjects: 120
Study 34536278 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Art Therapy (VAT) - 12 sessions over 6 weeks
Number of subjects: 127
Study 34536278 — intervention group
Group type: COMPARATOR
Intervention: Health Education - 6 sessions
Number of subjects: 127
Study 33053010 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching foot self‐care educational intervention
Number of subjects: 109
Study 33053010 — intervention group
Group type: COMPARATOR
Intervention: Control group (simply evaluated)
Number of subjects: 109
Study 36111921 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
Number of subjects: 20
Study 36111921 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE
Number of subjects: 20
Study 33495205 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised neuromuscular exercise (n = 36)
Number of subjects: 72
Study 33495205 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (n = 36)
Number of subjects: 72
Study 32665460 — intervention group
Group type: COMPARATOR
Intervention: Community ART groups (3MC)
Number of subjects: 5336
Study 32665460 — intervention group
Group type: COMPARATOR
Intervention: 6-monthly community distribution points (6MCD)
Number of subjects: 5336
Study 32665460 — intervention group
Group type: COMPARATOR
Intervention: 3MF (control)
Number of subjects: 5336
Study 32665460 — intervention group
Group type: COMPARATOR
Intervention: 3MC
Number of subjects: 5336
Study 32665460 — intervention group
Group type: COMPARATOR
Intervention: 6MCD
Number of subjects: 5336
Study 36028887 — intervention group
Group type: EXPERIMENTAL
Intervention: L-serine (3.0 g taken 30 min before bedtime for 2 weeks)
Number of subjects: 33
Study 36028887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 36028887 — intervention group
Group type: EXPERIMENTAL
Intervention: L-serine
Number of subjects: 33
Study 36028887 — intervention group
Group type: EXPERIMENTAL
Intervention: L-serine and Placebo
Number of subjects: 33
Study 34226572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhamnan sulphate (100 mg/day)
Number of subjects: 0
Study 34226572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32859235 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin combination therapy with standard antimicrobial treatment (cloxacillin or vancomycin)
Number of subjects: 99
Study 32859235 — intervention group
Group type: COMPARATOR
Intervention: Standard antimicrobial treatment (cloxacillin or vancomycin) without rifampin
Number of subjects: 99
Study 35500962 — intervention group
Group type: COMPARATOR
Intervention: Extension-oriented exercises (EE)
Number of subjects: 31
Study 35500962 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension exercises plus neurodynamic exercises (EEN)
Number of subjects: 31
Study 32356926 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0
Study 32356926 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34213957 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (170 μg)
Number of subjects: 48
Study 34213957 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D3 (20 μg)
Number of subjects: 48
Study 33471730 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI)
Number of subjects: 309
Study 33471730 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (IA)
Number of subjects: 309
Study 35151026 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PBM (30 J per site)
Number of subjects: 39
Study 35151026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 35151026 — intervention group
Group type: COMPARATOR
Intervention: Control (passive recovery)
Number of subjects: 39
Study 33145864 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/day of E. angustifolia fruit powder
Number of subjects: 58
Study 33145864 — intervention group
Group type: COMPARATOR
Intervention: 15 g/day of isomalt + corn starch (placebo)
Number of subjects: 58
Study 35360929 — intervention group
Group type: COMPARATOR
Intervention: Lobar hemorrhage
Number of subjects: 728
Study 35360929 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hemorrhage
Number of subjects: 728
Study 34064426 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal knee joint cooling (FKJC) for 20 minutes
Number of subjects: 21
Study 34064426 — intervention group
Group type: COMPARATOR
Intervention: Control condition (plastic ice bag filled with candy corn) for 20 minutes
Number of subjects: 21
Study 32121075 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of unprocessed or minimally processed foods
Number of subjects: 1919
Study 32121075 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of processed foods
Number of subjects: 1919
Study 32121075 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of ultra-processed food and drinks
Number of subjects: 1919
Study 32121075 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of unprocessed/minimally processed foods (high-grade cancers)
Number of subjects: 1919
Study 32121075 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of processed foods (high-grade cancers)
Number of subjects: 1919
Study 34460285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 68
Study 34460285 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Standard Community Treatment (ESCT)
Number of subjects: 68
Study 34592624 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct yoga therapy (YG; n = 35)
Number of subjects: 68
Study 34592624 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WG; n = 33)
Number of subjects: 68
Study 32532144 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention to reduce CVD events including drug therapy, lifestyle changes, and adherence support.
Number of subjects: 67
Study 32532144 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention to reduce CVD events.
Number of subjects: 67
Study 34412033 — intervention group
Group type: EXPERIMENTAL
Intervention: EDU‐ACT
Number of subjects: 32
Study 34412033 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 32107532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine plus ritonavir-boosted atazanavir
Number of subjects: 228
Study 32107532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir
Number of subjects: 228
Study 32107532 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 228
Study 32107532 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 228
Study 32366996 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week levofloxacin/dexamethasone eye drops followed by 1-week dexamethasone alone
Number of subjects: 808
Study 32366996 — intervention group
Group type: COMPARATOR
Intervention: 2-week tobramycin/dexamethasone eye drops
Number of subjects: 808
Study 32366996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 808
Study 36466503 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete group (n = 653)
Number of subjects: 6030
Study 36466503 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of AKI alerts detected by attending physicians (continuity variable)
Number of subjects: 6030
Study 33403821 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0
Study 33403821 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 0
Study 36479595 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,000 mg, twice daily)
Number of subjects: 84
Study 36479595 — intervention group
Group type: COMPARATOR
Intervention: Alogliptin (25 mg, once daily)
Number of subjects: 84
Study 36479595 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 84
Study 33438271 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 1106
Study 33438271 — intervention group
Group type: COMPARATOR
Intervention: Conventional cow's milk–based formula
Number of subjects: 1106
Study 32532766 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively framed life expectancy statement
Number of subjects: 271
Study 32532766 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchoring bias intervention
Number of subjects: 271
Study 34517434 — intervention group
Group type: EXPERIMENTAL
Intervention: FMDAP (full-mouth disinfection with adjuvant erythritol air-polishing)
Number of subjects: 172
Study 34517434 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD (full-mouth disinfection)
Number of subjects: 172
Study 34517434 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS (full-mouth scaling)
Number of subjects: 172
Study 34517434 — intervention group
Group type: COMPARATOR
Intervention: Q-SRP (quadrant-wise scaling and root planing)
Number of subjects: 172
Study 32633854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting
Number of subjects: 32
Study 32633854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting with PRP
Number of subjects: 32
Study 32633854 — intervention group
Group type: COMPARATOR
Intervention: Control (podiatry)
Number of subjects: 32
Study 32949984 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine
Number of subjects: 705
Study 32949984 — intervention group
Group type: EXPERIMENTAL
Intervention: Other metabolites
Number of subjects: 705
Study 32949984 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolinic acid
Number of subjects: 705
Study 32409760 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoids (Group A, n=73)
Number of subjects: 130
Study 32409760 — intervention group
Group type: EXPERIMENTAL
Intervention: Centella (Group B, n=66)
Number of subjects: 130
Study 32409760 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control Group C, n=60)
Number of subjects: 130
Study 32409760 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoids (Group A)
Number of subjects: 130
Study 32409760 — intervention group
Group type: EXPERIMENTAL
Intervention: Centella (Group B)
Number of subjects: 130
Study 32409760 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control Group C)
Number of subjects: 130
Study 32409760 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoids
Number of subjects: 130
Study 35905031 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in exercise after hospitalization
Number of subjects: 292
Study 35905031 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy for exercise at 6 months post-discharge
Number of subjects: 292
Study 35905031 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of functional ability at discharge
Number of subjects: 292
Study 35905031 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a partner
Number of subjects: 292
Study 35905031 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in exercise prior to hospital admission
Number of subjects: 292
Study 35905031 — intervention group
Group type: EXPERIMENTAL
Intervention: College or university education
Number of subjects: 292
Study 35905031 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prior to hospital admission
Number of subjects: 292
Study 35905031 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a partner at discharge
Number of subjects: 292
Study 35905031 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher functional ability at discharge
Number of subjects: 292
Study 35048310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilizing our Voices for Empowerment (MOVE)
Number of subjects: 54
Study 35048310 — intervention group
Group type: COMPARATOR
Intervention: Comparison health promotion intervention
Number of subjects: 54
Study 34427806 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise intervention
Number of subjects: 260
Study 34427806 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 260
Study 32237945 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (terazosin and nifedipine)
Number of subjects: 165
Study 32237945 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study 32237945 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 165
Study 35287231 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 609
Study 35287231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 36373413 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT with Compassion (ACTwC)
Number of subjects: 5
Study 33336889 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil (PR)
Number of subjects: 50
Study 33336889 — intervention group
Group type: COMPARATOR
Intervention: Propofol only (PP)
Number of subjects: 50
Study 32416926 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 60
Study 32416926 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 33641624 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired Life Programme (ILP), a 10-session group-based multicomponent positive psychology intervention
Number of subjects: 18
Study 32438479 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 24
Study 32438479 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 24
Study 34924275 — intervention group
Group type: EXPERIMENTAL
Intervention: CFSAT plus speed focused CCT
Number of subjects: 117
Study 34924275 — intervention group
Group type: COMPARATOR
Intervention: CFSAT training alone
Number of subjects: 117
Study 33260142 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 1 (25-ml solution, 2 mM of quinine)
Number of subjects: 12
Study 33260142 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 2 (replicate of Quinine 1)
Number of subjects: 12
Study 33260142 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (25-ml sweet-tasting no-carbohydrate solution)
Number of subjects: 12
Study 33260142 — intervention group
Group type: COMPARATOR
Intervention: Control (25 ml of water)
Number of subjects: 12
Study 32108529 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdosing LSD (13 mcg, 11.3% of one tab)
Number of subjects: 909
Study 32108529 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdosing psilocybin (0.3 g of dried psilocybin mushrooms)
Number of subjects: 909
Study 32108529 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdosing (LSD or psilocybin)
Number of subjects: 909
Study 35915040 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga with slow breathing instructions (Vinyasa)
Number of subjects: 54
Study 35915040 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga with no breathing instructions
Number of subjects: 54
Study 35915040 — intervention group
Group type: COMPARATOR
Intervention: Seated rest with slow breathing instructions
Number of subjects: 54
Study 35915040 — intervention group
Group type: COMPARATOR
Intervention: Seated rest with no breathing instructions
Number of subjects: 54
Study 33615980 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic status (b: −12.37; p < .001)
Number of subjects: 3094